{"hands_on_practices": [{"introduction": "Understanding the mechanisms of antibiotic resistance in *Neisseria gonorrhoeae* begins at the molecular level of drug-target interactions. This exercise models the critical binding event between a cephalosporin antibiotic and its target, penicillin-binding protein 2 (PBP2), using fundamental principles of chemical kinetics. By quantifying how a 'mosaic' mutation alters the drug's binding affinity and subsequent target occupancy, you will gain a quantitative appreciation for how genetic adaptations directly undermine antibiotic efficacy, a central challenge in treating gonorrhea [@problem_id:4672340].", "problem": "Neisseria gonorrhoeae frequently acquires decreased susceptibility to extended-spectrum cephalosporins through mosaic alterations in penicillin-binding protein 2 (PBP2). Consider the reversible pre-acylation binding step of a cephalosporin drug $D$ to PBP2, modeled as $D + P \\rightleftharpoons DP$ with bimolecular association rate constant $k_{\\mathrm{on}}$ and first-order dissociation rate constant $k_{\\mathrm{off}}$. Under conditions where the reversible binding step reaches quasi-equilibrium rapidly relative to downstream acylation, the equilibrium dissociation constant $K_{d}$ for this step is defined by the law of mass action and depends on the kinetic parameters of the interaction. Assume simple $1{:}1$ binding with no cooperativity and that the total PBP2 concentration is low enough that the free drug concentration can be treated as the nominal $[D]$.\n\nSurface plasmon resonance experiments at $37\\,\\mathrm{^\\circ C}$ yield the following kinetic parameters for ceftriaxone binding to wild-type and mosaic PBP2:\n- Wild-type PBP2: $k_{\\mathrm{on,wt}} = 8.0 \\times 10^{5}\\ \\mathrm{M^{-1}\\,s^{-1}}$ and $k_{\\mathrm{off,wt}} = 4.0 \\times 10^{-3}\\ \\mathrm{s^{-1}}$.\n- Mosaic PBP2: $k_{\\mathrm{on,mos}} = 3.0 \\times 10^{5}\\ \\mathrm{M^{-1}\\,s^{-1}}$ and $k_{\\mathrm{off,mos}} = 1.5 \\times 10^{-2}\\ \\mathrm{s^{-1}}$.\n\nAt a free drug concentration of $[D] = 1.0 \\times 10^{-7}\\ \\mathrm{M}$, determine the fold change in equilibrium occupancy of the reversible complex $DP$ for mosaic PBP2 relative to wild-type PBP2, defined as the ratio $\\theta_{\\mathrm{mos}} / \\theta_{\\mathrm{wt}}$, where $\\theta$ denotes the fraction of PBP2 molecules in the $DP$ complex at equilibrium. Round your final ratio to four significant figures and express it as a decimal without a percentage sign.", "solution": "The problem is scientifically grounded, well-posed, and objective. All necessary data and definitions for a unique solution are provided. The underlying principles are standard in chemical kinetics and pharmacology, and the biological context is factually correct. Therefore, the problem is valid and a solution can be derived.\n\nThe problem describes the reversible binding of a drug, $D$, to a protein, $P$ (PBP2), to form a complex, $DP$. The reaction is modeled as:\n$$\nD + P \\rightleftharpoons DP\n$$\nThe rate of the forward (association) reaction is given by $R_{\\mathrm{on}} = k_{\\mathrm{on}} [D] [P]$, where $k_{\\mathrm{on}}$ is the bimolecular association rate constant. The rate of the reverse (dissociation) reaction is given by $R_{\\mathrm{off}} = k_{\\mathrm{off}} [DP]$, where $k_{\\mathrm{off}}$ is the first-order dissociation rate constant.\n\nThe problem states that this binding step reaches quasi-equilibrium. At equilibrium, the rate of association equals the rate of dissociation:\n$$\nR_{\\mathrm{on}} = R_{\\mathrm{off}}\n$$\n$$\nk_{\\mathrm{on}} [D] [P] = k_{\\mathrm{off}} [DP]\n$$\nThe equilibrium dissociation constant, $K_d$, is defined by the law of mass action as $K_d = \\frac{[D][P]}{[DP]}$. By rearranging the rate equality, we can express $K_d$ in terms of the kinetic rate constants:\n$$\nK_d = \\frac{k_{\\mathrm{off}}}{k_{\\mathrm{on}}}\n$$\nThe fractional occupancy, $\\theta$, is the fraction of total protein that is in the drug-bound state, $[DP]$. The total protein concentration is $[P]_{\\text{total}} = [P] + [DP]$.\n$$\n\\theta = \\frac{[DP]}{[P]_{\\text{total}}} = \\frac{[DP]}{[P] + [DP]}\n$$\nTo express $\\theta$ in terms of the drug concentration $[D]$ and the dissociation constant $K_d$, we first rearrange the definition of $K_d$ to solve for the free protein concentration, $[P]$:\n$$\n[P] = \\frac{K_d [DP]}{[D]}\n$$\nSubstituting this into the expression for $\\theta$:\n$$\n\\theta = \\frac{[DP]}{\\frac{K_d [DP]}{[D]} + [DP]}\n$$\nThe term $[DP]$ appears in the numerator and in each term of the denominator, so it can be canceled:\n$$\n\\theta = \\frac{1}{\\frac{K_d}{[D]} + 1} = \\frac{[D]}{K_d + [D]}\n$$\nThis is the Hill-Langmuir equation for $1{:}1$ binding.\n\nWe first calculate the equilibrium dissociation constants for the wild-type (wt) and mosaic (mos) forms of PBP2 using the provided kinetic parameters.\n\nFor wild-type PBP2:\n$k_{\\mathrm{on,wt}} = 8.0 \\times 10^{5}\\ \\mathrm{M^{-1}\\,s^{-1}}$\n$k_{\\mathrm{off,wt}} = 4.0 \\times 10^{-3}\\ \\mathrm{s^{-1}}$\n$$\nK_{d,\\mathrm{wt}} = \\frac{k_{\\mathrm{off,wt}}}{k_{\\mathrm{on,wt}}} = \\frac{4.0 \\times 10^{-3}\\ \\mathrm{s^{-1}}}{8.0 \\times 10^{5}\\ \\mathrm{M^{-1}\\,s^{-1}}} = 0.5 \\times 10^{-8}\\ \\mathrm{M} = 5.0 \\times 10^{-9}\\ \\mathrm{M}\n$$\nFor mosaic PBP2:\n$k_{\\mathrm{on,mos}} = 3.0 \\times 10^{5}\\ \\mathrm{M^{-1}\\,s^{-1}}$\n$k_{\\mathrm{off,mos}} = 1.5 \\times 10^{-2}\\ \\mathrm{s^{-1}}$\n$$\nK_{d,\\mathrm{mos}} = \\frac{k_{\\mathrm{off,mos}}}{k_{\\mathrm{on,mos}}} = \\frac{1.5 \\times 10^{-2}\\ \\mathrm{s^{-1}}}{3.0 \\times 10^{5}\\ \\mathrm{M^{-1}\\,s^{-1}}} = 0.5 \\times 10^{-7}\\ \\mathrm{M} = 5.0 \\times 10^{-8}\\ \\mathrm{M}\n$$\nNext, we express the fractional occupancies for both variants using the derived binding equation and the given drug concentration $[D] = 1.0 \\times 10^{-7}\\ \\mathrm{M}$.\n$$\n\\theta_{\\mathrm{wt}} = \\frac{[D]}{K_{d,\\mathrm{wt}} + [D]}\n$$\n$$\n\\theta_{\\mathrm{mos}} = \\frac{[D]}{K_{d,\\mathrm{mos}} + [D]}\n$$\nThe problem asks for the fold change in equilibrium occupancy, which is the ratio $\\frac{\\theta_{\\mathrm{mos}}}{\\theta_{\\mathrm{wt}}}$.\n$$\n\\frac{\\theta_{\\mathrm{mos}}}{\\theta_{\\mathrm{wt}}} = \\frac{\\frac{[D]}{K_{d,\\mathrm{mos}} + [D]}}{\\frac{[D]}{K_{d,\\mathrm{wt}} + [D]}}\n$$\nSimplifying this complex fraction yields:\n$$\n\\frac{\\theta_{\\mathrm{mos}}}{\\theta_{\\mathrm{wt}}} = \\frac{K_{d,\\mathrm{wt}} + [D]}{K_{d,\\mathrm{mos}} + [D]}\n$$\nNow we substitute the calculated $K_d$ values and the given $[D]$:\n$$\n\\frac{\\theta_{\\mathrm{mos}}}{\\theta_{\\mathrm{wt}}} = \\frac{5.0 \\times 10^{-9}\\ \\mathrm{M} + 1.0 \\times 10^{-7}\\ \\mathrm{M}}{5.0 \\times 10^{-8}\\ \\mathrm{M} + 1.0 \\times 10^{-7}\\ \\mathrm{M}}\n$$\nTo facilitate the addition, we can express all concentrations with a common power of $10$, for instance $10^{-7}$:\n$$\n\\frac{\\theta_{\\mathrm{mos}}}{\\theta_{\\mathrm{wt}}} = \\frac{0.05 \\times 10^{-7}\\ \\mathrm{M} + 1.0 \\times 10^{-7}\\ \\mathrm{M}}{0.5 \\times 10^{-7}\\ \\mathrm{M} + 1.0 \\times 10^{-7}\\ \\mathrm{M}} = \\frac{(0.05 + 1.0) \\times 10^{-7}\\ \\mathrm{M}}{(0.5 + 1.0) \\times 10^{-7}\\ \\mathrm{M}}\n$$\n$$\n\\frac{\\theta_{\\mathrm{mos}}}{\\theta_{\\mathrm{wt}}} = \\frac{1.05 \\times 10^{-7}\\ \\mathrm{M}}{1.5 \\times 10^{-7}\\ \\mathrm{M}} = \\frac{1.05}{1.5} = 0.7\n$$\nThe calculated ratio is exactly $0.7$. The problem requires the final answer to be rounded to four significant figures. Therefore, the result should be expressed as $0.7000$. This indicates that at a drug concentration of $1.0 \\times 10^{-7}\\ \\mathrm{M}$, the occupancy of the mosaic PBP2 is $70\\%$ of the occupancy of the wild-type PBP2.", "answer": "$$\\boxed{0.7000}$$", "id": "4672340"}, {"introduction": "Moving from the molecular scale to the population level, this practice explores the epidemiological dynamics that drive the spread of gonorrhea. You will apply the core concept of the basic reproduction number, $R_0$, to model how behavioral and biological factors contribute to sustained transmission within different populations. This exercise provides hands-on experience in building a simple infectious disease model and using it to assess why gonorrhea persists and to estimate the efficacy required for public health interventions to succeed [@problem_id:4672298].", "problem": "A core definition in infectious disease epidemiology is the basic reproduction number $R_0$, defined as the expected number of secondary infections generated by a single infectious individual introduced into a fully susceptible population. Consider Neisseria gonorrhoeae transmission in two behaviorally distinct subpopulations: a general heterosexual group and a high-turnover Men who have sex with men (MSM) core group. In each group, assume that new sexual partnerships for an infectious individual are formed as a Poisson process at rate $c$ partnerships per year, and that each partnership formed while infectious results in transmission with probability $\\beta$ that is independent across partnerships. The duration of infectiousness $D$ for an untreated case is determined by a mixture of symptomatic and asymptomatic courses: with probability $s$ the case is symptomatic and is treated after $T$ years, and with probability $1 - s$ the case is asymptomatic and clears in $L$ years.\n\nUse these assumptions and definitions to derive, from first principles, an expression for $R_0$ in terms of $\\beta$, $c$, and $D$. Then apply it to the following scenarios:\n\nGeneral heterosexual scenario:\n- Symptomatic probability $s_{\\mathrm{het}} = 0.6$.\n- Time to treatment if symptomatic $T_{\\mathrm{het}} = 0.15$ years.\n- Natural clearance time if asymptomatic $L_{\\mathrm{het}} = 0.8$ years.\n- Per-partnership transmission probability $\\beta_{\\mathrm{het}} = 0.35$.\n- Partnership formation rate $c_{\\mathrm{het}} = 4$ partnerships per year.\n\nMSM core scenario:\n- Symptomatic probability $s_{\\mathrm{MSM}} = 0.5$.\n- Time to treatment if symptomatic $T_{\\mathrm{MSM}} = 0.10$ years.\n- Natural clearance time if asymptomatic $L_{\\mathrm{MSM}} = 1.0$ years.\n- Per-partnership transmission probability $\\beta_{\\mathrm{MSM}} = 0.60$.\n- Partnership formation rate $c_{\\mathrm{MSM}} = 12$ partnerships per year.\n\nTasks:\n1. Derive an expression for $D$ from the symptomatic/asymptomatic mixture described above, and then derive an expression for $R_0$ based on the expected number of partnerships formed while infectious and the per-partnership transmission probability.\n2. Compute $R_0$ for each scenario and state whether it exceeds $1$.\n3. Suppose an intervention (for example, condom use or effective antimicrobial prophylaxis) reduces the per-partnership transmission probability multiplicatively by a factor $1 - \\rho$, where $0 \\leq \\rho \\leq 1$. Determine the minimum value of $\\rho$ required to guarantee that $R_0 < 1$ in both scenarios simultaneously.\n\nProvide your final numerical answer as the value of $\\rho$ required in task $3$, rounded to four significant figures. Express $\\rho$ as a decimal fraction (not a percentage).", "solution": "The problem statement is evaluated as scientifically grounded, well-posed, and objective. It presents a standard epidemiological modeling exercise based on established principles and provides all necessary parameters for a unique solution. The problem is therefore deemed valid.\n\nThe solution will be developed in three parts as requested by the problem statement.\n\n**Task $1$: Derivation of expressions for $D$ and $R_0$**\n\nThe duration of infectiousness is a random variable that depends on whether an infection is symptomatic or asymptomatic. Let $D$ denote the expected duration of infectiousness. With probability $s$, the case is symptomatic and has a duration of $T$. With probability $1-s$, the case is asymptomatic and has a duration of $L$. The expected duration is the weighted average of these two outcomes:\n$$D = s \\cdot T + (1 - s) \\cdot L$$\n\nThe basic reproduction number, $R_0$, is defined as the expected number of secondary infections produced by a single infectious individual in a completely susceptible population. This can be calculated as the product of three factors: the rate of new partnership formation ($c$), the probability of transmission per partnership ($\\beta$), and the duration of infectiousness ($D$).\nThe total number of partnerships formed during the infectious period is the rate $c$ multiplied by the duration $D$. Thus, the expected number of partnerships is $c \\cdot D$.\nSince each partnership leads to a transmission with probability $\\beta$, the expected number of total transmissions is:\n$$R_0 = \\beta \\cdot c \\cdot D$$\nSubstituting the expression for the expected duration $D$, we obtain the full expression for $R_0$ from first principles:\n$$R_0 = \\beta \\cdot c \\cdot [s \\cdot T + (1-s) \\cdot L]$$\n\n**Task $2$: Computation of $R_0$ for each scenario**\n\nWe will now apply the derived formula to the two specified scenarios.\n\nGeneral heterosexual scenario:\nThe parameters are $s_{\\mathrm{het}} = 0.6$, $T_{\\mathrm{het}} = 0.15$ years, $L_{\\mathrm{het}} = 0.8$ years, $\\beta_{\\mathrm{het}} = 0.35$, and $c_{\\mathrm{het}} = 4$ per year.\nFirst, we compute the expected duration of infectiousness, $D_{\\mathrm{het}}$:\n$$D_{\\mathrm{het}} = s_{\\mathrm{het}} \\cdot T_{\\mathrm{het}} + (1 - s_{\\mathrm{het}}) \\cdot L_{\\mathrm{het}}$$\n$$D_{\\mathrm{het}} = (0.6) \\cdot (0.15) + (1 - 0.6) \\cdot (0.8)$$\n$$D_{\\mathrm{het}} = 0.09 + (0.4) \\cdot (0.8) = 0.09 + 0.32 = 0.41 \\text{ years}$$\nNext, we compute the basic reproduction number, $R_{0, \\mathrm{het}}$:\n$$R_{0, \\mathrm{het}} = \\beta_{\\mathrm{het}} \\cdot c_{\\mathrm{het}} \\cdot D_{\\mathrm{het}}$$\n$$R_{0, \\mathrm{het}} = (0.35) \\cdot (4) \\cdot (0.41) = 1.4 \\cdot 0.41 = 0.574$$\nFor this scenario, $R_{0, \\mathrm{het}} = 0.574$, which does not exceed $1$.\n\nMSM core scenario:\nThe parameters are $s_{\\mathrm{MSM}} = 0.5$, $T_{\\mathrm{MSM}} = 0.10$ years, $L_{\\mathrm{MSM}} = 1.0$ year, $\\beta_{\\mathrm{MSM}} = 0.60$, and $c_{\\mathrm{MSM}} = 12$ per year.\nFirst, we compute the expected duration of infectiousness, $D_{\\mathrm{MSM}}$:\n$$D_{\\mathrm{MSM}} = s_{\\mathrm{MSM}} \\cdot T_{\\mathrm{MSM}} + (1 - s_{\\mathrm{MSM}}) \\cdot L_{\\mathrm{MSM}}$$\n$$D_{\\mathrm{MSM}} = (0.5) \\cdot (0.10) + (1 - 0.5) \\cdot (1.0)$$\n$$D_{\\mathrm{MSM}} = 0.05 + (0.5) \\cdot (1.0) = 0.05 + 0.5 = 0.55 \\text{ years}$$\nNext, we compute the basic reproduction number, $R_{0, \\mathrm{MSM}}$:\n$$R_{0, \\mathrm{MSM}} = \\beta_{\\mathrm{MSM}} \\cdot c_{\\mathrm{MSM}} \\cdot D_{\\mathrm{MSM}}$$\n$$R_{0, \\mathrm{MSM}} = (0.60) \\cdot (12) \\cdot (0.55) = 7.2 \\cdot 0.55 = 3.96$$\nFor this scenario, $R_{0, \\mathrm{MSM}} = 3.96$, which exceeds $1$.\n\n**Task $3$: Determination of minimum intervention efficacy $\\rho$**\n\nAn intervention reduces the per-partnership transmission probability $\\beta$ to a new value $\\beta' = \\beta(1-\\rho)$. The new basic reproduction number, which we denote $R_0'$, is then:\n$$R_0' = \\beta' \\cdot c \\cdot D = \\beta(1-\\rho) \\cdot c \\cdot D = (1-\\rho) R_0$$\nThe condition is that $R_0' < 1$ must be satisfied in both scenarios simultaneously.\n\nFor the heterosexual scenario:\n$$R'_{0, \\mathrm{het}} = (1-\\rho) R_{0, \\mathrm{het}} = (1-\\rho) \\cdot 0.574 < 1$$\nSince $R_{0, \\mathrm{het}} < 1$, and the problem states $0 \\le \\rho \\le 1$ (which implies $0 \\le 1-\\rho \\le 1$), the product $(1-\\rho) R_{0, \\mathrm{het}}$ will be at most $0.574$, which is always less than $1$. Thus, this condition is satisfied for any permissible value of $\\rho$.\n\nFor the MSM core scenario:\n$$R'_{0, \\mathrm{MSM}} = (1-\\rho) R_{0, \\mathrm{MSM}} = (1-\\rho) \\cdot 3.96 < 1$$\nThis is the stricter, or binding, condition. To find the minimum value of $\\rho$ that guarantees this inequality, we solve for $\\rho$ at the critical threshold where $R'_{0, \\mathrm{MSM}} = 1$.\n$$(1-\\rho) \\cdot 3.96 = 1$$\n$$1 - \\rho = \\frac{1}{3.96}$$\n$$\\rho = 1 - \\frac{1}{3.96}$$\nTo guarantee that $R'_{0, \\mathrm{MSM}} < 1$, we must have $\\rho > 1 - \\frac{1}{3.96}$. The minimum required value is therefore the critical value itself.\n$$\\rho = 1 - \\frac{1}{3.96} = \\frac{3.96 - 1}{3.96} = \\frac{2.96}{3.96}$$\n$$\\rho = \\frac{296}{396} = \\frac{74}{99}$$\nAs a decimal, this is $\\rho = 0.747474...$.\nThe problem requires the answer to be rounded to four significant figures.\nThe fifth significant figure is $7$, so we round the fourth figure up.\n$$\\rho \\approx 0.7475$$\nThis value of $\\rho$ is the minimum required to bring the basic reproduction number below $1$ in the high-transmission group, and by extension, in both groups.", "answer": "$$\\boxed{0.7475}$$", "id": "4672298"}, {"introduction": "Effective public health control of gonorrhea hinges on accurate and reliable diagnostics, yet the interpretation of test results is a nuanced, probabilistic exercise. This final practice bridges theory and application by examining the performance of Nucleic Acid Amplification Tests (NAATs) in a mixed-population screening program [@problem_id:4672268]. By applying Bayes' theorem, you will learn to calculate the positive and negative predictive values, distinguishing a test's intrinsic properties (sensitivity and specificity) from its practical utility in making informed clinical and public health decisions.", "problem": "A public health clinic deploys a Nucleic Acid Amplification Test (NAAT) for detection of Neisseria gonorrhoeae across two specimen types that differ in performance due to biological and ecological factors. The definitions to be used are: sensitivity is $P(\\text{Test} + \\mid \\text{Disease})$, specificity is $P(\\text{Test} - \\mid \\neg \\text{Disease})$, and prevalence is $P(\\text{Disease})$. The clinic tests one specimen per patient, with a known mixture of specimen types. Empirically, for urogenital specimens ($u$), the sensitivity is $s_{u} = 0.97$, the specificity is $c_{u} = 0.995$, and the prevalence among those tested is $p_{u} = 0.08$. For pharyngeal specimens ($p$), the sensitivity is $s_{p} = 0.92$, the specificity is $c_{p} = 0.985$, and the prevalence among those tested is $p_{p} = 0.05$. The specimen-type mix is $w_{u} = 0.60$ urogenital and $w_{p} = 0.40$ pharyngeal, with $w_{u} + w_{p} = 1$.\n\nAssume the test outcome for a given specimen type is conditionally independent of population mixing beyond its dependence on the specimen type and true disease status, and that the biological definitions above hold exactly. Using Bayesâ€™ theorem and the law of total probability applied across the specimen-type mixture, compute the overall positive predictive value $PPV = P(\\text{Disease} \\mid \\text{Test} +)$ and negative predictive value $NPV = P(\\neg \\text{Disease} \\mid \\text{Test} -)$ for the aggregate NAAT results produced by this program. Report both $PPV$ and $NPV$ as decimal values rounded to four significant figures.", "solution": "The problem is valid as it is scientifically grounded in epidemiology, well-posed with all necessary information, and free of contradictions or ambiguities. We proceed with the solution.\n\nLet the following events be defined:\n- $D$: The patient has the disease (*Neisseria gonorrhoeae* infection).\n- $\\neg D$: The patient does not have the disease.\n- $T+$: The NAAT result is positive.\n- $T-$: The NAAT result is negative.\n- $U$: The specimen is urogenital.\n- $P$: The specimen is pharyngeal.\n\nThe provided parameters can be expressed in probabilistic terms:\n- Sensitivity for urogenital specimens: $s_u = P(T+ \\mid D, U) = 0.97$\n- Specificity for urogenital specimens: $c_u = P(T- \\mid \\neg D, U) = 0.995$\n- Prevalence in the urogenital-tested subpopulation: $p_u = P(D \\mid U) = 0.08$\n- Sensitivity for pharyngeal specimens: $s_p = P(T+ \\mid D, P) = 0.92$\n- Specificity for pharyngeal specimens: $c_p = P(T- \\mid \\neg D, P) = 0.985$\n- Prevalence in the pharyngeal-tested subpopulation: $p_p = P(D \\mid P) = 0.05$\n- Proportion of urogenital specimens: $w_u = P(U) = 0.60$\n- Proportion of pharyngeal specimens: $w_p = P(P) = 0.40$\n\nWe need to compute the overall positive predictive value, $PPV = P(D \\mid T+)$, and the overall negative predictive value, $NPV = P(\\neg D \\mid T-)$.\n\nBy definition of conditional probability (Bayes' theorem):\n$$PPV = P(D \\mid T+) = \\frac{P(D \\cap T+)}{P(T+)}$$\n$$NPV = P(\\neg D \\mid T-) = \\frac{P(\\neg D \\cap T-)}{P(T-)}$$\n\nWe will compute the components of these expressions using the law of total probability, conditioning on the specimen type ($U$ or $P$).\n\nFirst, we calculate the numerator for the $PPV$, which is the total probability of having the disease and testing positive, $P(D \\cap T+)$.\n$$P(D \\cap T+) = P(D \\cap T+ \\mid U)P(U) + P(D \\cap T+ \\mid P)P(P)$$\nUsing the definition of conditional probability, $P(A \\cap B \\mid C) = P(A \\mid B, C)P(B \\mid C)$:\n$$P(D \\cap T+) = P(T+ \\mid D, U)P(D \\mid U)P(U) + P(T+ \\mid D, P)P(D \\mid P)P(P)$$\nSubstituting the given symbolic names:\n$$P(D \\cap T+) = s_u p_u w_u + s_p p_p w_p$$\n$$P(D \\cap T+) = (0.97)(0.08)(0.60) + (0.92)(0.05)(0.40)$$\n$$P(D \\cap T+) = 0.04656 + 0.0184 = 0.06496$$\n\nNext, we calculate the denominator for the $PPV$, which is the total probability of testing positive, $P(T+)$.\n$$P(T+) = P(T+ \\mid D)P(D) + P(T+ \\mid \\neg D)P(\\neg D)$$\nAn alternative and more direct approach is to sum the joint probabilities of a positive test with disease and without disease:\n$$P(T+) = P(T+ \\cap D) + P(T+ \\cap \\neg D)$$\nWe already have $P(T+ \\cap D) = 0.06496$. We now compute $P(T+ \\cap \\neg D)$.\nUsing the law of total probability again:\n$$P(T+ \\cap \\neg D) = P(T+ \\mid \\neg D, U)P(\\neg D \\mid U)P(U) + P(T+ \\mid \\neg D, P)P(\\neg D \\mid P)P(P)$$\nWe use the fact that specificity $c = P(T- \\mid \\neg D)$, so $P(T+ \\mid \\neg D) = 1 - c$. Also, $P(\\neg D \\mid S) = 1 - P(D \\mid S) = 1 - p_S$ for specimen type $S$.\n$$P(T+ \\cap \\neg D) = (1-c_u)(1-p_u)w_u + (1-c_p)(1-p_p)w_p$$\n$$P(T+ \\cap \\neg D) = (1-0.995)(1-0.08)(0.60) + (1-0.985)(1-0.05)(0.40)$$\n$$P(T+ \\cap \\neg D) = (0.005)(0.92)(0.60) + (0.015)(0.95)(0.40)$$\n$$P(T+ \\cap \\neg D) = 0.00276 + 0.0057 = 0.00846$$\nNow, we can find the total probability of a positive test:\n$$P(T+) = 0.06496 + 0.00846 = 0.07342$$\nFinally, we compute the $PPV$:\n$$PPV = \\frac{P(D \\cap T+)}{P(T+)} = \\frac{0.06496}{0.07342} \\approx 0.88477254...$$\nRounding to four significant figures, $PPV = 0.8848$.\n\nNow, we compute the $NPV$. First, we calculate the numerator, $P(\\neg D \\cap T-)$.\n$$P(\\neg D \\cap T-) = P(T- \\mid \\neg D, U)P(\\neg D \\mid U)P(U) + P(T- \\mid \\neg D, P)P(\\neg D \\mid P)P(P)$$\n$$P(\\neg D \\cap T-) = c_u(1-p_u)w_u + c_p(1-p_p)w_p$$\n$$P(\\neg D \\cap T-) = (0.995)(1-0.08)(0.60) + (0.985)(1-0.05)(0.40)$$\n$$P(\\neg D \\cap T-) = (0.995)(0.92)(0.60) + (0.985)(0.95)(0.40)$$\n$$P(\\neg D \\cap T-) = 0.54924 + 0.3743 = 0.92354$$\n\nNext, we calculate the denominator, $P(T-)$. The simplest way is to use the complement of $P(T+)$.\n$$P(T-) = 1 - P(T+) = 1 - 0.07342 = 0.92658$$\nAlternatively, we can compute it from its components: $P(T-) = P(T- \\cap D) + P(T- \\cap \\neg D)$. We have $P(T- \\cap \\neg D) = 0.92354$. We need $P(T- \\cap D)$.\n$$P(T- \\cap D) = P(T- \\mid D, U)P(D \\mid U)P(U) + P(T- \\mid D, P)P(D \\mid P)P(P)$$\nUsing $P(T- \\mid D) = 1 - s$:\n$$P(T- \\cap D) = (1-s_u)p_u w_u + (1-s_p)p_p w_p$$\n$$P(T- \\cap D) = (1-0.97)(0.08)(0.60) + (1-0.92)(0.05)(0.40)$$\n$$P(T- \\cap D) = (0.03)(0.08)(0.60) + (0.08)(0.05)(0.40)$$\n$$P(T- \\cap D) = 0.00144 + 0.0016 = 0.00304$$\nSo, $P(T-) = P(T- \\cap \\neg D) + P(T- \\cap D) = 0.92354 + 0.00304 = 0.92658$. This confirms the result from $1-P(T+)$.\n\nFinally, we compute the $NPV$:\n$$NPV = \\frac{P(\\neg D \\cap T-)}{P(T-)} = \\frac{0.92354}{0.92658} \\approx 0.9967190...$$\nRounding to four significant figures, $NPV = 0.9967$.\n\nThe overall Positive Predictive Value ($PPV$) is $0.8848$ and the overall Negative Predictive Value ($NPV$) is $0.9967$.", "answer": "$$\n\\boxed{\n\\begin{pmatrix}\n0.8848 & 0.9967\n\\end{pmatrix}\n}\n$$", "id": "4672268"}]}